A Critical Review of the Use of Botulinum Toxin in Orofacial Pain Disorders

Dental Clinics of North America

Volumn 51, Issue 1, 2007, Pages 245-261

  Clark, Glenn T ^a   Stiles, Alan ^b   Lockerman, Larry Z ^c   Gross, Sheldon G ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; MUSCLE RELAXANT AGENT;

ANIMAL; FACE PAIN; HUMAN; METHODOLOGY; MYOFASCIAL PAIN; NERVE BLOCK; REVIEW; TEMPOROMANDIBULAR JOINT DISORDER;

ANIMALS; BOTULINUM TOXINS; FACIAL PAIN; HUMANS; MYOFASCIAL PAIN SYNDROMES; NERVE BLOCK; NEUROMUSCULAR AGENTS; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 33845475455     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2006.09.003     Document Type: Review

References (52)

1. Schantz E.J. Historical perspective. In: Jankovic J., and Hallett M. (Eds). Therapy with botulinum toxin (1994), Marcel Dekker, New York p. xxiii-xxvi
2. Coffield J.A., Considine R.V., and Simpson L.L. The site and mechanism of action of botulinum toxin. In: Jankovic J., and Hallett M. (Eds). Therapy with botulinum toxin (1994), Marcel Dekker, New York 3-13
3. Anderson E.R. Non-cosmetic uses of botulinum neurotoxin: scientific and clinical update. Am J Health Syst Pharm 61 Suppl 6 (2004) S3-S4
4. Use of botulinum toxin-A in pain associated with neuromuscular disorders. Available at: http://www.health.state.mn.us/htac/botox.htm. Accessed October 21, 2006.
5. Clark G.T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 14 4 (2003) 727-748
6. Meunier F.A., Schiavo G., and Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol (Paris) 96 1-2 (2002) 105-113
7. Bhidayasiri R., and Truong D.D. Expanding use of botulinum toxin. J Neurol Sci 235 1-2 (2005) 1-9
8. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43 Suppl 1 (2003) S9-S15
9. Dressler D., and Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 53 1 (2005) 3-9
10. Alam M., Arndt K.A., and Dover J.S. Severe, intractable headache after injection with botulinum A exotoxin: Report of 5 cases. J Am Acad Dermatol 46 1 (2002) 62-65
11. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 2 (2000) 245-258
12. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 1 (2004) 35-43
13. Chuang Y.C., Yoshimura N., Huang C.C., et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172 4 Pt 1 (2004) 1529-1532
14. Cui M., Khanijou S., Rubino J., et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
15. Bach-Rojecky L., and Lackovic Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J 46 2 (2005) 201-208
16. Fielder T., and Durham P.L. Stimulation of CGRP secretion from trigeminal ganglia neurons by nitric oxide and repression by botulinum toxin type A. Soc Neurosci Abstr Viewer Itiner (2003) ABS588.6
17. Blersch W., Schulte-Mattler W.J., Przywara S., et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 1 (2002) 59-63
18. Barwood S., Baillieu C., Boyd R., et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 42 2 (2000) 116-121
19. Sycha T., Kranz G., Auff E., et al. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol 251 Suppl 1 (2004) I19-I30
20. De Andres J., Cerda-Olmedo G., Valia J.C., et al. Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain 19 4 (2003) 269-275
21. Qerama E., Fuglsang-Frederiksen A., Kasch H., et al. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 67 2 (2006) 241-245
22. Ojala T., Arokoski J.P., and Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 22 1 (2006) 90-96
23. Ferrante F.M., Bearn L., Rothrock R., et al. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 103 2 (2005) 377-383
24. Graboski C.L., Shaun Gray D., and Burnham R.S. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 118 1-2 (2005) 170-175
25. Kamanli A., Kaya A., Ardicoglu O., et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 25 8 (2005) 604-611
26. Freund B., Schwartz M., and Symington J.M. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg 57 8 (1999) 916-920 [discussion 920-1]
27. Freund B., Schwartz M., and Symington J.M. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38 5 (2000) 466-471
28. Freund B.J., and Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 42 10 (2002) 1033-1037
29. von Lindern J.J. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 101 1 (2001) 39-41
30. Karacalar A., Yilmaz N., Bilgici A., et al. Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience. J Craniofac Surg 16 3 (2005) 476-481
31. von Lindern J.J., Niederhagen B., Berge S., et al. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 61 7 (2003) 774-778
32. Nixdorf D.R., Heo G., and Major P.W. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 99 3 (2002) 465-473
33. Klein A.W., and Glogau R.G. Botulinum toxin: beyond cosmesis. Arch Dermatol 136 4 (2000) 539-541
34. Barrientos N., Chana P., De la Cerda A., et al. Efficacy and safety of botulinum toxin in migraine: 1-year follow-up. J Neurol Sci 214 1-2 (2003) 91
35. Binder W.J., Brin M.F., Blitzer A., et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123 6 (2000) 669-676
36. Krusz J.C. Intradermal botulinum toxin type B for migraine of cervical origin. Am J Pain Manag 14 3 (2004) 81-84
37. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 251 Suppl 1 (2004) I8-I11
38. Silberstein S., Mathew N., Saper J., et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 6 (2000) 445-450
39. Evers S., Vollmer-Haase J., Schwaag S., et al. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 10 (2004) 838-843
40. Dodick D.W., Mauskop A., Elkind A.H., et al. BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 4 (2005) 315-324
41. Relja M., and Telarovic S. Botulinum toxin in tension-type headache. J Neurol 251 Suppl 1 (2004) I12-I14
42. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43 8 (2003) 853-860
43. Schmitt W.J., Slowey E., Fravi N., et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 41 7 (2001) 658-664
44. Padberg M., de Bruijn S.F., de Haan R.J., et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 24 8 (2004) 675-680
45. Schulte-Mattler W.J., and Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 109 1-2 (2004) 110-114
46. Silberstein S.D., Gobel H., Jensen R., et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26 7 (2006) 790-800
47. Mathew N.T., Frishberg B.M., Gawel M., et al. BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45 4 (2005) 293-307
48. Kern U., Martin C., Scheicher S., et al. [Treatment of phantom pain with botulinum-toxin A. A pilot study.]. Schmerz 17 2 (2003) 117-124 [in German]
49. Borodic G.E., and Acquadro M.A. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 3 (2002) 21-27
50. Türk U., Ilhan S., Alp R., et al. Botulinum toxin A and intractable trigeminal neuralgia. Clin Neuropharmacol 28 (2005) 161-162
51. Allam N., Brasil-Neto J.P., Brown G., et al. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 21 2 (2005) 182-184
52. Piovesan E.J., Teive H.G., Kowacs P.A., et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65 8 (2005) 1306-1308